X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): THR-687
Therapeutic Area: Ophthalmology Product Name: THR-687
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 25, 2021
Details:
Oxurion expecting to begin the Phase 2 development of THR-687 in DME in mid-2021 and are on-track to deliver the initial Part A data from the Phase 2 trial with THR-149 in DME later this year as planned.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): THR-149
Therapeutic Area: Ophthalmology Product Name: THR-149
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2021
Details:
THR-149, Oxurion’s most advanced drug candidate, is being developed to potentially become the treatment of choice for the up to 40% of DME patients, who respond suboptimally to anti-VEGF therapy.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): THR-149
Therapeutic Area: Ophthalmology Product Name: THR-149
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 13, 2021
Details:
THR-149 is a potential first in class plasma kallikrein inhibitor with the possibility to become the treatment of choice for the 40% DME patients who respond sub-optimally to anti-VEGF therapy.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
